A Phase 1b/2a, Open-label Multi-Centre Dose-Escalation and Expansion Study of DM199, in Participants undergoing Expectant Management for Preterm Preeclampsia
Pre-eclampsia is a serious condition that causes high blood pressure during pregnancy. When it happens early, doctors often watch mothers closely in hospital to keep the pregnancy going safely for as long as possible. This is called expectant management. This early-stage clinical trial is looking at a new medicine called DM199. Researchers want to find out if DM199 is safe and well tolerated by pregnant women and their unborn babies. They will check the levels of the medicine in the mother's blood, in the umbilical cord after birth, and in breast milk. The trial also looks at whether DM199 can help keep blood pressure stable and safely extend pregnancy, giving babies more time to grow before birth. Taking part is voluntary, and participants receive close medical monitoring throughout their stay.
Överblick
Vad handlar denna studie om?
Pre-eclampsia is a condition that develops during pregnancy, usually marked by high blood pressure and signs of stress on organs like the kidneys. When pre-eclampsia develops early (preterm), it can be dangerous for both mother and baby. The only cure is giving birth, but delivering a baby too early brings health challenges. Doctors often try to safely delay delivery for as long as possible to give the baby vital time to grow, while keeping the mother safe.
This study tests an experimental medicine called DM199. Researchers want to see if this medicine can help support the mother's blood vessels, stabilise blood pressure, and allow the pregnancy to safely continue for extra days or weeks. Because every extra day in the womb can make a meaningful difference to a premature baby's health, finding new treatments for pre-eclampsia is an urgent medical goal.
This is an early-phase trial, meaning it is one of the first times DM199 is being tested in pregnant women. The main goal is to check its safety, find the best dose, and understand how the body processes the drug. The research team will measure drug levels in the mother's blood, in breast milk, and in the umbilical cord blood collected after birth.
By taking part, mothers help doctors learn whether DM199 could become a useful treatment for preterm pre-eclampsia in the future. The trial is carefully run in hospital under expert supervision to ensure maternal and fetal safety at all times.
Viktiga punkter
- Tests a new medicine, DM199, for women with early pre-eclampsia.
- Aims to check safety and see if pregnancies can be safely extended.
- Open to women aged 18 and over who are being closely monitored in hospital.
- Tracks medicine levels in maternal blood, cord blood, and breast milk.
- Participation is voluntary and includes close medical care throughout.
Vem kan vara berättigad?
This trial is open to pregnant women aged 18 and older who have been diagnosed with preterm pre-eclampsia. Preterm means the condition has appeared before the pregnancy reaches full term.
To be considered, doctors must already be managing the pregnancy with close monitoring (expectant management) rather than planning an immediate emergency delivery. This means both mother and baby are currently stable enough for pregnancy to safely continue under hospital observation.
Women who need immediate delivery due to severe complications, or who have other medical issues that make the trial medicine unsafe, will not be eligible. Your hospital care team will carry out detailed checks to confirm whether taking part is safe for you.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- I am aged 18 or older.
- I am currently pregnant and have not yet reached full term.
- I have been diagnosed with pre-eclampsia.
- My doctors are using expectant management (monitoring me closely rather than delivering immediately).
- I am being cared for in a hospital taking part in this study.
Vad innebär deltagande?
If you take part, you will receive the study medicine, DM199, while being looked after in hospital. Doctors will test different doses across groups of participants to find the safest amount. You will have regular checks, including frequent blood pressure monitoring, blood tests, and scans to check your baby's wellbeing. After you give birth, the research team will test a small sample of blood from the umbilical cord and take samples of your breast milk to see how much medicine passes through. Your overall participation lasts from when you start the medicine until a short follow-up period after delivery.
Potentiella risker och fördelar
Platser (1)
- —ObekräftadTyskland
Vanliga frågor
What is preterm pre-eclampsia?
It is a condition during pregnancy causing high blood pressure and protein in the urine before the 37th week, which can lead to early birth.
Will taking this medicine harm my baby?
The study is designed with strict safety checks to protect both you and your baby, but because it is a new medicine, all risks are not yet fully known.
Do I have to pay to take part?
No, clinical trials run in NHS hospitals do not cost you anything, and all trial medicines and extra tests are provided free of charge.
Can I still breastfeed if I join?
Yes, researchers will test small samples of your breast milk or first milk (colostrum) to check medicine levels, and the team will advise you on feeding.
Kan jag lämna studien om jag ändrar mig?
Yes, you can leave the study at any time. Your decision will not change the standard of medical care you and your baby receive.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.